Study Sheds Light on Vaccine Efficacy in Older Adults
A recent study has delved into why certain vaccines, like those for COVID-19 and influenza, tend to be less effective in older adults compared to younger individuals. It might actually change how we understand aging itself.
Previously, researchers largely blamed the diminished vaccine response in older adults on a general decline in the immune system as one ages. There’s been a lot of focus on ongoing, low-level immune activation, often referred to as inflammaging, which was thought to contribute to this decline.
However, this new study comparing older and younger adults found that there aren’t consistent increases in biological markers of inflammation as people age. Instead, aging seems to reprogram T cells—those crucial immune cells that assist in activating B cells to generate antibodies against various viruses and vaccines.
Published on October 29 in the journal Nature, the findings might suggest that inflammation isn’t as central to aging as previously believed.
“We think inflammation is influenced by factors other than just a person’s age,” remarked Claire Gustafson, an assistant investigator at the Allen Institute for Immunology and one of the study’s lead authors.
In light of these discoveries, Alan Cohen, an associate professor specializing in aging and inflammation at Columbia University, commented that the results support a more nuanced view of “inflammaging.” He noted that while the concept of inflammation increasing with age might hold true for many in industrialized societies, it certainly doesn’t apply universally.
Cohen also pointed out the study’s participants were solely from Palo Alto, California, and Seattle, two highly developed regions. Since significant differences in inflammation exist when comparing populations from places like Italy, Singapore, Bolivia, and Malaysia, he indicated that these results may not translate across different environments.
“It’s important not to read this as a definitive declaration that there’s no change in inflammation with age,” Cohen cautioned. “Instead, it serves as an example of a group whose immune response may not align with typical expectations.”
T Cell Changes Beyond Inflammation
To enhance vaccine responses in older adults, Gustafson and her team investigated how T cells evolve with age.
They initially compared a younger group (ages 25 to 35) with an older bunch (ages 55 to 65—deemed the “cusp of aging”). Over two years, researchers followed 96 healthy volunteers from both age brackets, taking blood samples eight to ten times and assessing their immune responses after annual flu shots. Then, they expanded their study to include 234 individuals aged 40 to over 90.
By utilizing advanced techniques like single-cell RNA sequencing, the researchers analyzed genetic material, specifically RNA, within immune cells. This revealed which proteins were being produced at specific times. They also employed high-dimensional plasma proteomics to examine circulating proteins in the blood.
The researchers identified notable differences in memory T cells, crucial for remembering past infections and enabling quicker responses. In older adults, many memory T cells transitioned into a state that altered their interaction with B cells, which in turn made B cells less efficient at producing antibodies against infections or vaccines. On the flip side, the memory T cells of younger adults were quicker to ramp up the expected antibody response.
These immune modifications seemed to occur independently of inflammation and infections from dormant viruses, known as latent viruses, which can linger in the body post-infection. It was often believed these viruses, like cytomegalovirus (CMV), contributed to age-related immune system declines. However, the study noted that those under 65 who had experienced a CMV infection didn’t show signs of accelerated immune aging or higher inflammatory protein levels.
Cohen expressed caution regarding the study’s conclusions, emphasizing that significant immune changes typically arise post-65. “If you don’t notice a difference in inflammation between 25 to 35 and 55 to 65, could it be because inflammation doesn’t actually shift with age, or is it simply that they haven’t aged enough yet to notice?” he pondered.
The researchers proposed that these insights could help in designing vaccines tailored to address age-related immune shifts, ultimately enhancing protection for older adults. They are hopeful this could also inform treatments aimed at restoring immune functionality in older populations.
